Clinical Candidates

MTL-005: an enhancement to x-ray irradiation therapy

MTL-005 is a new targeted therapy for cancers treated with conventional radiotherapy.  The product has been out-licensed to MorEx Development Partners LLP and is undergoing pre-clinical development.

MTL-007: a novel anti-cancer prodrug

MTL-007 is a modified nucleoside based upon Gemzar® (gemcitabine: Eli Lilly).  This product, together with its associated proTide platform technology, has been out-licensed to Nucana Biomed Ltd (www.nucanbiomed.com).

MTL-003: anti-angiogenic cancer therapy 

MTL-003 is Morvus’ lead biological compound. It is a novel, hybrid molecule combining anti-angiogenic activity and endothelial cell regulatory activity. MTL-003 has almost completed its research phase prior to entering full development.  This protein comprises two functional sequences each with a different mode of action and so has the potential for dual action giving rise to a greater anti-cancer activity.

MTL-003 has the following technical advantages over comparable treatments: 

• broader spectrum of action than other systems;

• direct action on endothelial cells and most importantly on cancer cells;
• dual action opens the possibility of overcoming acquired resistance to anti-angiogenesis therapies.
  
  

MTL-004: a local cytotoxic agent

MTL-004 is a potent cytotoxic agent which has a very short range. Further, its mechanism of action requires the target cell to attempt to divide before the cytotoxic effect is manifested.Thus it can be a potent anti-tumour agent but its effect on most normal cells is minimal (as they divide less often). Morvus is exploring various clinical applications for this potent topical agent.